AstraZeneca PLC said on Monday that results from its TOPAZ-1 Phase 3 trial on its human monoclonal antibody, Imfinzi, showed it significantly improved overall survival in advanced biliary tract cancer patients.
The London-listed pharmaceutical company said Imfinzi, in combination with standard-of-care chemotherapy, showed a "statistically significant and clinically meaningful" overall survival when compared with chemotherapy alone.
"We believe the significant survival benefit demonstrated marks a new era of immunotherapy treatment in this devastating disease, and it advances our commitment to improving long-term survival for patients across these cancers where treatment options are limited," the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.